Cerevel Therapeutics Holdings, Inc. (CERE) has a consensus analyst rating of Hold, based on 16 analysts covering the stock. Of those, 6 recommend buying, 10 recommend holding, and 0 recommend selling.
The analyst consensus price target for CERE is $33.50, representing a -25.5% downside from the current price of $44.96. Price targets range from a low of $27.00 to a high of $40.00.
